ESPE Abstracts (2024) 98 P2-144

ESPE2024 Poster Category 2 GH and IGFs (22 abstracts)

Growth Aberrations in a Yemeni Girl with Elevated IGF-1 Due to a PAPPA2 Gene Mutation: A Case Report

Sohair Elsiddig , Ashraf Soliman , Fawzia Alyafei , Nada Alaaraj , Noor Hamed & Shayma Ahmed


Hamad General Hospital, Doha, Qatar


Introduction: The PAPPA2 gene plays a crucial role in growth regulation through its interaction with the insulin-like growth factor (IGF) system. Mutations in this gene can lead to disrupted growth patterns. This case report describes the clinical course of a Yemeni girl with a pathogenic PAPPA2 variant, characterized by high IGF-1 levels and affected linear growth and weight gain.

Case Presentation: A 5-year-old girl of Yemeni descent, born preterm at 35 weeks with intrauterine growth restriction (IUGR), presented with failure to thrive and short stature. Initially, her measurements were significantly below the mean for her gestational age, with a birth weight of 1.7 kg (-3.7 SDS), length of 45 cm (-1.7 SDS), and head circumference of 42 cm (-2 SDS). Despite normal metabolic, immunological, and gastrointestinal function tests, her growth remained stunted. Whole exome sequencing identified a homozygous pathogenic variant in the PAPPA2 gene. Nutritional interventions led to intermittent improvements in growth metrics. However, discontinuation of a high-calorie, high-protein diet resulted in a decline in her growth velocity, which was later restored with oral nutritional supplementation.

Results: The patient showed marked fluctuations in weight and height standard deviation scores (SDS) and growth velocity (GV) over time, with notable decreases during periods of inadequate nutrition. The Introduction of a high-calorie, high-protein diet through nasogastric tube (NGT) feeding initially improved weight and growth velocity, but the cessation of this diet led to negative growth outcomes. Reinitiation of oral nutritional supplements corresponded with improvements in growth parameters and IGF-1 levels, although these remained above average.

Table: Growth and IGF1 levels during the 5 years of life
Age Wt WAZ Length LAZ WLZ GV Weight gain/d IGF1 IGF1SDS
14 mo. 7.3 -2.00 71.0 -2.00 -2.00 22cm/yr. 5g/day
18 mo 7.9 -2.90 75.0 -1.98 -1.35 10g/day 399 8
27 mo. 11.6 -0.34 84.7 -1.00 0.40 12cm/yr. 8g/day 610 11.2
3 yrs 13.0 -0.77 94.0 -0.74 -0.50 9.6cm/yr. 4g/day 562 10.6
4 yrs 12.4 -1.94 98.0 -0.94 -2.00 8.6cm/yr. 2g/day
4.5 yrs 15.0 -0.90 101.0 -0.50 -0.50 20g/day 503 7.7
5.5 yrs 17.5 -0.56 111.0 -0.14 -0.74 9cm/yr. 7g/day

Conclusion: This case underscores the importance of nutritional management in patients with growth disorders associated with PAPPA2 mutations. It highlights the complexities of growth regulation in the context of genetic abnormalities and the potential reversibility of growth deficits with appropriate interventions. Regular follow-up and adherence to nutritional guidelines are imperative for managing similar cases.

Volume 98

62nd Annual ESPE (ESPE 2024)

Liverpool, UK
16 Nov 2024 - 18 Nov 2024

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.